The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Atypical Antipsychotic Agents in the Treatment of Violent Patients With Schizophrenia and Schizoaffective Disorder
Abstract
CONTEXT: Violent behavior of patients with schizophrenia prolongs hospital stay and interferes with their integration into the community. Finding appropriate treatment of violent behaviors is of primary importance. OBJECTIVE: To compare the efficacy of 2 atypical antipsychotic agents, clozapine and olanzapine, with one another and with haloperidol in the treatment of physical assaults and other aggressive behaviors in physically assaultive patients with schizophrenia and schizoaffective disorder. DESIGN AND SETTING: Randomized, double-blind, parallel-group, 12-week trial. Physically assaultive subjects with schizophrenia or schizoaffective disorder who were inpatients in state psychiatric facilities were randomly assigned to treatment with clozapine (n = 37), olanzapine (n = 37), or haloperidol (n = 36). MAIN OUTCOME MEASURES: Number and severity of physical assaults as measured by the Modified Overt Aggression Scale (MOAS) physical aggression score and the number and severity of all aggressive events as measured by the MOAS overall score. Psychiatric symptoms were assessed through the Positive and Negative Syndrome Scale (PANSS). RESULTS: Clozapine was superior to both olanzapine and haloperidol in reducing the number and severity of physical assaults as assessed by the MOAS physical aggression score and in reducing overall aggression as measured by the MOAS total score. Olanzapine was superior to haloperidol in reducing the number and severity of aggressive incidents on these 2 MOAS measures. There were no significant differences among the 3 medication groups in improvement of psychiatric symptoms as measured by the PANSS total score and the 3 PANSS subscales. CONCLUSIONS: Clozapine shows greater efficacy than olanzapine and olanzapine greater efficacy than haloperidol in reducing aggressive behavior. This antiaggressive effect appears to be separate from the antipsychotic and sedative action of these medications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
Swanson, J. W., Holzer, C. E., Ganju, V. K., & Jono, R. T. (1990) · Psychiatric Services · doi:10.1176/ps.41.7.761 · Cited by 1,277
A Meta-analysis of the Efficacy of Second-Generation Antipsychotics
Davis, J. M., Chen, N., & Glick, I. D. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.6.553 · Cited by 1,034
Miyamoto, S., Duncan, G. E., Marx, C. E., & Lieberman, J. A. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001556 · Cited by 988 · cited 1×
“The new atypical agents differ pharmacologically from previous antipsychotic agents in their lower affinity for dopamine D2 receptors and greater affinities for serotonin (5-hydroxytryptamine1A, 2A, 2C, 3, 6, and 7) and norepinephrine 1 and 2 neuroreceptors.(9,10) Norepinephrine and especially serotonin have been impl…”
BackgroundViolence and Severe Mental Illness: The Effects of Substance Abuse and Nonadherence to Medication
Swartz, M. S., Swanson, J. W., Hiday, V. A., Borum, R., Wagner, H. R., & Burns, B. J. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.2.226 · Cited by 634
Profiles of Aggression among Psychiatric Patients: I. Nature and Prevalence
KAY, S. R., WOLKENFELD, F., & MURRILL, L. M. (1988) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-198809000-00007 · Cited by 468
Rosenheck, R. (2003) · JAMA · doi:10.1001/jama.290.20.2693 · Cited by 326
Mental disorder, substance abuse, and community violence: An epidemiological approach.
Swanson, J. W. (1994) · Cited by 267
Buchanan, R. W., Breier, A., Kirkpatrick, B., Ball, P., & Carpenter, W. T. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.6.751 · Cited by 264
The Effects of Clozapine on Alcohol and Drug Use Disorders Among Patients With Schizophrenia
Drake, R. E., Xie, H., McHugo, G. J., & Green, A. I. (2000) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033464 · Cited by 253
Cited by
Neurobiology of Aggression and Violence
Siever, L. J. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.07111774 · Cited by 984
“Antagonists of 5-HT2A receptors reduce impulsivity in animal models (65), and atypical neuroleptics with prominent 5-HT2A antagonism have antiaggressive efficacy in clinical populations (66).”
BackgroundThe 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements
Buchanan, R. W., Kreyenbuhl, J., Kelly, D. L., Noel, J. M., Boggs, D. L., Fischer, B. A., Himelhoch, S., Fang, B., Peterson, E., Aquino, P. R., et al. (2010) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp116 · Cited by 907
Barnes, T. R., Drake, R., Paton, C., Cooper, S. J., Deakin, B., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I., et al. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 606
Miyamoto, S., Miyake, N., Jarskog, L. F., Fleischhacker, W. W., & Lieberman, J. A. (2012) · Molecular Psychiatry · doi:10.1038/mp.2012.47 · Cited by 573
Olanzapine versus other atypical antipsychotics for schizophrenia
Komossa, K., Rummel-Kluge, C., Hunger, H., Schmid, F., Schwarz, S., Duggan, L., Kissling, W., & Leucht, S. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006654.pub2 · Cited by 365
Barnes, T. R., & the Schizophrenia Consensus Group of the British Association for Psychopharmacology (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110391123 · Cited by 356
Quetiapine versus other atypical antipsychotics for schizophrenia
Komossa, K., Rummel-Kluge, C., Schmid, F., Hunger, H., Schwarz, S., Srisurapanont, M., Kissling, W., & Leucht, S. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006625.pub2 · Cited by 260
A systematic review of the evidence of clozapine's anti-aggressive effects
Frogley, C., Taylor, D., Dickens, G., & Picchioni, M. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s146114571100201x · Cited by 252
Barros, C. S., Calabrese, B., Chamero, P., Roberts, A. J., Korzus, E., Lloyd, K., Stowers, L., Mayford, M., Halpain, S., & Müller, U. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900355106 · Cited by 197
Monoamine-sensitive developmental periods impacting adult emotional and cognitive behaviors
Suri, D., Teixeira, C. M., Cagliostro, M. K. C., Mahadevia, D., & Ansorge, M. S. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2014.231 · Cited by 167
Hoptman, M. J., Antonius, D., Mauro, C. J., Parker, E. M., & Javitt, D. C. (2014) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2014.13111553 · Cited by 152
Qayyum, A., C. Zai, C., Hirata, Y., K. Tiwari, A., Cheema, S., Nowrouzi, B., Beitchman, J., & Kennedy, L. (2015) · Current Neuropharmacology · doi:10.2174/1570159x13666150612225836 · Cited by 95
Cheng, N., Ma, H., Zhang, K., Zhang, C., & Geng, D. (2023) · Medicina · doi:10.3390/medicina59030503 · Cited by 17
Metadata
- Authors
- Krakowski, M. I., Czobor, P., Citrome, L., Bark, N., & Cooper, T. B.
- Venue
- Archives of General Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 2006-06-01
- Volume
- 63
- Issue
- 6
- Pages
- 622
- ISSN
- 0003-990X (ISSN-L)
- OpenAlex
- W2147322097
- Cited by
- 352
- References
- 33
- FWCI
- 11.69
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.